Corcept Therapeutics (CORT) Operating Expenses (2010 - 2026)

Corcept Therapeutics has disclosed Operating Expenses across 17 years of filings, most recently posting $214.5 million for Q1 2026.

• Operating Expenses for Q1 2026 came in at $214.5 million, up 39.47% year-over-year; the trailing twelve-month figure through Mar 2026 was $777.3 million (up 35.28% YoY), and the FY2025 annual result was $716.6 million, up 33.18% from the prior year.
• Operating Expenses came in at $214.5 million for Q1 2026 at Corcept Therapeutics, up from $197.6 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $214.5 million in Q1 2026 to a low of $66.9 million in Q1 2022.
• The 5-year median for Operating Expenses is $117.3 million (2024), against an average of $125.5 million.
• Across the five-year window, Operating Expenses gained 11.91% in 2022 and surged 50.99% in 2024, its largest moves.
• Corcept Therapeutics' Operating Expenses stood at $80.6 million in 2022, then climbed by 28.77% to $103.7 million in 2023, then soared by 50.99% to $156.6 million in 2024, then grew by 26.18% to $197.6 million in 2025, then advanced by 8.53% to $214.5 million in 2026.
• The last three Operating Expenses figures came in at $214.5 million (Q1 2026), $197.6 million (Q4 2025), and $197.4 million (Q3 2025), per Business Quant data.